Chronic AR
The treatment of chronic AR depends on 5 factors:
Whether the regurgitation is mild, moderate, or severe
Whether the patient is asymptomatic or symptomatic
Whether the patient has normal left ventricular (LV) function or LV dysfunction
Whether the patient has LV dilation
Whether the patient is a surgical candidate.
Mild to moderate disease
Patients with mild to moderate disease (American College of Cardiology/American Heart Association [ACC/AHA] stage B, progressive AR) who are asymptomatic with normal LV function do not require treatment and can be reassured. In patients with this degree of AR severity, symptoms or LV dysfunction, if present, are unlikely to be due to AR. An alternative underlying cause such as hypertension, coronary artery disease, or a cardiomyopathy is more likely and should be investigated and treated. Periodic follow-up for symptom and functional status evaluation is recommended.
In patients with moderate disease who are undergoing cardiac surgery for another indication, concomitant aortic valve replacement can be considered.[1]Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Feb 2;77(4):e25-197.
https://www.sciencedirect.com/science/article/pii/S0735109720377962
http://www.ncbi.nlm.nih.gov/pubmed/33342586?tool=bestpractice.com
Severe disease
Patients who have asymptomatic AR with LV ejection fraction (LVEF) >55% and LV end-systolic diameter (LVESD) <50 mm (ACC/AHA stage C1) require no treatment and the patient can be reassured. Periodic follow-up for symptom and functional status evaluation is recommended. If the patient is undergoing cardiac surgery for another indication, concomitant aortic valve replacement can be considered.[1]Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Feb 2;77(4):e25-197.
https://www.sciencedirect.com/science/article/pii/S0735109720377962
http://www.ncbi.nlm.nih.gov/pubmed/33342586?tool=bestpractice.com
Note that in European Society of Cardiology (ESC) guidelines, the threshold for intervention in asymptomatic patients is LVEF <50%.[22]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
Aortic valve surgery is indicated in asymptomatic patients with chronic severe AR and LVEF ≤55% (ACC/AHA stage C2), if no other cause for systolic dysfunction is identified. Aortic valve surgery is also reasonable in patients with normal LV systolic function (LVEF >55%) when the LV is severely enlarged (LVESD >50 mm or indexed LVESD >25 mm/m²).[1]Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Feb 2;77(4):e25-197.
https://www.sciencedirect.com/science/article/pii/S0735109720377962
http://www.ncbi.nlm.nih.gov/pubmed/33342586?tool=bestpractice.com
[26]National Institute for Health and Care Excellence. Heart valve disease presenting in adults: investigation and management. Nov 2021 [internet publication].
https://www.nice.org.uk/guidance/ng208
Surgery can also be considered in patients with chronic severe AR and LVEF >55% at rest (ACC/AHA stage C1) who have a low surgical risk and a progressive decline in LVEF to low-normal range (55% to 60%) or progressive increase in LV end-diastolic diameter (>65 mm) on at least 3 studies.[1]Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Feb 2;77(4):e25-197.
https://www.sciencedirect.com/science/article/pii/S0735109720377962
http://www.ncbi.nlm.nih.gov/pubmed/33342586?tool=bestpractice.com
In patients who have severe AR with LV systolic dysfunction and/or symptoms but a prohibitive surgical risk, guideline-directed medical therapy (GDMT) for reduced LVEF and/or hypertension is recommended.[1]Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Feb 2;77(4):e25-197.
https://www.sciencedirect.com/science/article/pii/S0735109720377962
http://www.ncbi.nlm.nih.gov/pubmed/33342586?tool=bestpractice.com
All symptomatic patients require surgery, regardless of their LV function and dilation.[1]Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Feb 2;77(4):e25-197.
https://www.sciencedirect.com/science/article/pii/S0735109720377962
http://www.ncbi.nlm.nih.gov/pubmed/33342586?tool=bestpractice.com
[22]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
[26]National Institute for Health and Care Excellence. Heart valve disease presenting in adults: investigation and management. Nov 2021 [internet publication].
https://www.nice.org.uk/guidance/ng208
Vasodilators may be used for symptomatic management while the patient is awaiting surgery.[1]Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Feb 2;77(4):e25-197.
https://www.sciencedirect.com/science/article/pii/S0735109720377962
http://www.ncbi.nlm.nih.gov/pubmed/33342586?tool=bestpractice.com
If the patient is not a surgical candidate due to comorbidities, GDMT for reduced LVEF and/or hypertension is recommended.[1]Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Feb 2;77(4):e25-197.
https://www.sciencedirect.com/science/article/pii/S0735109720377962
http://www.ncbi.nlm.nih.gov/pubmed/33342586?tool=bestpractice.com
The surgical options are aortic valve replacement (AVR) or repair. There is no difference in the indications for replacement or repair. AVR is performed in most patients requiring surgery. Aortic valve repair is possible in selected patients but is only performed in specialist centres. Following surgery, most of the patients show reversal of LV dilation and improvement in EF. Preoperative LV function is the best predictor of long-term prognosis in patients undergoing AVR.[27]Gaasch WH, Andrias CW, Levine HJ. Chronic aortic regurgitation: the effect of aortic valve replacement on left ventricular volume, mass and function. Circulation. 1978 Nov;58(5):825-36.
http://circ.ahajournals.org/content/58/5/825.long
http://www.ncbi.nlm.nih.gov/pubmed/151609?tool=bestpractice.com
Patients with normal preoperative EF or a brief duration of LV dysfunction (<14 months) have greater improvement in LV diameters and early and late postoperative improvement in LV function.[28]Bonow RO, Dodd JT, Maron BJ, et al. Long-term serial changes in left ventricular function and reversal of ventricular dilatation after valve replacement for chronic aortic regurgitation. Circulation. 1988 Nov;78(5 Pt 1):1108-20.
http://circ.ahajournals.org/content/78/5/1108.long
http://www.ncbi.nlm.nih.gov/pubmed/2972417?tool=bestpractice.com
Among patients with LV dysfunction, patients with impaired preoperative LV function have a greater risk of developing congestive heart failure and are at a higher risk of death compared with patients with normal preoperative LV function.[29]Bonow RO, Picone AL, McIntosh CL, et al. Survival and functional results after valve replacement for aortic regurgitation from 1976 to 1983: impact of preoperative left ventricular function. Circulation. 1985 Dec;72(6):1244-56.
http://circ.ahajournals.org/content/72/6/1244.long
http://www.ncbi.nlm.nih.gov/pubmed/4064269?tool=bestpractice.com
Survival among patients with preoperative severe LV dysfunction has improved dramatically since 1985 and has become almost equivalent to that among patients with non-severe LV dysfunction. Prosthetic valve patients are at high risk for thromboembolism and need antithrombotic therapy. The risk of bleeding must be weighed against the benefit of anticoagulation.
Transcatheter aortic valve implantation (TAVI) can be considered for carefully selected patients with severe AR and heart failure who are not surgical candidates, but it is rarely done.[1]Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Feb 2;77(4):e25-197.
https://www.sciencedirect.com/science/article/pii/S0735109720377962
http://www.ncbi.nlm.nih.gov/pubmed/33342586?tool=bestpractice.com
[22]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632.
https://academic.oup.com/eurheartj/article/43/7/561/6358470
http://www.ncbi.nlm.nih.gov/pubmed/34453165?tool=bestpractice.com
TAVI is not recommended for those with isolated severe AR who have indications for surgery and are candidates for surgery.[1]Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Feb 2;77(4):e25-197.
https://www.sciencedirect.com/science/article/pii/S0735109720377962
http://www.ncbi.nlm.nih.gov/pubmed/33342586?tool=bestpractice.com